White House announces its largest set of most-favored-nation pricing deals to date

On December 19, 2025, the White House announced what it called its largest set of most-favored-nation (MFN) pricing deals to date, expanding a pricing push that began earlier in the year beyond the first companies to sign on ^[1]. The move came weeks before the administration launched TrumpRx.gov, a website meant to let patients buy certain brand-name drugs at discounted prices ^[1].

According to a White House fact sheet tied to the site's launch, the administration reached 16 deals with major pharmaceutical manufacturers between September 30, 2025, and early February 2026 ^[1]. The effort traces back to a May 12, 2025 executive order on MFN pricing and July 31, 2025 letters the administration sent to drugmakers outlining steps for bringing US prices closer to what other wealthy nations pay ^[1]. The fact sheet does not name which specific manufacturers were added in the December 19 round, so it is not yet known which companies' deals made up this particular announcement ^[1].

The first five manufacturers to sign MFN deals — AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer — had their drugs featured when TrumpRx.gov opened on February 5, 2026, with the fact sheet stating that drugs from additional companies would be added "in the coming months" ^[1]. Among the listed changes: the monthly price of Ozempic (semaglutide) was set to fall from $1,028 to an average of $350, and as low as $199 depending on dosage strength ^[1]. Injectable Wegovy (semaglutide) was set to drop from $1,349 to an average of $350, as low as $199, while the Wegovy pill was set to fall to as low as $149 ^[1]. Zepbound (tirzepatide) was set to drop from $1,088 to an average of $346, as low as $299 ^[1]. The source does not give pricing details for Mounjaro, Rybelsus, or orforglipron (Foundayo).

The broader pricing push also included a December 1, 2025 trade agreement in which the United Kingdom agreed to raise the net price of new prescription drugs by 25%, which the administration described as making other countries "pay their fair share" ^[1]. On January 15, 2026, President Trump called on Congress to pass what the fact sheet calls the Great Healthcare Plan, which would codify MFN savings into law alongside other insurance changes ^[1].

Why it matters for patients

For people taking semaglutide or tirzepatide products, these announcements point toward substantially lower list prices — potentially cutting monthly costs by roughly two-thirds for some doses — but only through the TrumpRx.gov channel and only for patients with a valid prescription ^[1]. The fact sheet describes savings delivered through printable or downloadable coupons or manufacturer-run channels linked to the site, not necessarily through standard insurance billing ^[1]. It is not yet known from these sources how this program interacts with existing insurance coverage, Medicare, or Medicaid, or whether patients who already pay lower copays through insurance would see any change at all.

Because discounts vary by dosage strength and the December 19 announcement itself does not list which manufacturers were newly added, patients cannot yet know from public information exactly which products or doses were affected by that specific round of deals ^[1].

What happens next

The fact sheet states that drugs from additional manufacturers with signed MFN deals would be added to TrumpRx.gov "in the coming months" after the February 5, 2026 launch ^[1]. Separately, the administration's January 15, 2026 call for Congress to pass the Great Healthcare Plan aims to write MFN pricing savings into law, though the fact sheet does not include a timeline for congressional action ^[1].